Maze Therapeutics, Inc. Common Stock

MAZENASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
24.27 USD
↘ 1.13 (4.45%)AT CLOSE (11:59 AM EDT)
24.25
↘ 0.02 (0.08%)
POST MARKET (AS OF 04:31 PM EDT)
Post Market
AS OF 04:31 PM EDT
24.25
↘ 0.02 (0.08%)
🔴Market: CLOSED
Open?$25.47
High?$25.68
Low?$23.62
Prev. Close?$25.40
Volume?445.6K
Avg. Volume?494.3K
VWAP?$24.26
Rel. Volume?0.90x
Bid / Ask
Bid?$19.78 × 100
Ask?$31.30 × 100
Spread?$11.52
Midpoint?$25.54
Valuation & Ratios
Market Cap?1.3B
Shares Out?55.3M
Float?28.2M
Float %?58.6%
P/E Ratio?N/A
P/B Ratio?3.93
EPS?-$2.21
Dividend?0.00%
Ex-Dividend?N/A

MAZE is currently priced at $24.27. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Themes
Biotech - Drug Development›Metabolic & CardiometabolicHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
141
Market Cap
1.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.mazetx.com
Listed
2025-01-31
Address
171 OYSTER POINT BOULEVARD, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 850-5070
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
77
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?8.64Safe
Confidence?41%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?14.02%High
Short Interest?4.0M
Days to Cover?7.4
Free Float28.2M
Avg Daily Volume533.2K
Settlement Date2026-05-15
Financial Health
Current Ratio?17.88Strong
Quick Ratio?17.88Strong
Cash Ratio?9.36Strong
Debt/Equity?0.11Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
45
3.93FAIR▾
P/S?
Peers
100
S&P
3
67.16HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-9.0CHEAP▾
EV/Sales?
Peers
100
S&P
3
59.16HIGH▾
Returns & Efficiency
ROE?
S&P
5
-35.9%WEAK▾
ROA?
S&P
3
-29.2%WEAK▾
Cash Flow & Enterprise
FCF?$-122125000
Enterprise Value?$1.2B
Fundamentals ratios updated end of day
MarketsMoversWatchlist